背景:动静脉畸形(AVM)可以通过观察来治疗,手术,栓塞,立体定向放射外科(SRS)或联合治疗。SRS已被用于构成手术高风险的AVM,例如在深层或雄辩的解剖位置。较小的AVM,<3cm,已被证明在SRS后有更高的完全消失率。对于较大尺寸的AVM,SRS之前的栓塞已用于减少AVMnidus的大小。在这项研究中,我们分析了SRS之前的栓塞以减少nidal体积,并描述了针对SRS栓塞后的成像技术。
方法:我们回顾性地回顾了一个学术机构在SRS治疗AVM之前接受栓塞治疗的所有患者。然后,我们使用对比增强磁共振成像(MRI)根据栓塞前的成像并与栓塞后的成像进行比较来确定AVM的体积。然后将栓塞之前的计划AVM体积与实际治疗的AVM体积进行比较。
结果:我们确定了2011-2023年在SRS之前接受栓塞治疗的11例患者。栓塞前AVM的平均体积为7.69cc,栓塞后为3.61cc(p<0.01)。在我们的系列随访中,有45.5%的闭塞率,有2个与放射外科有关的小并发症。
结论:在我们的队列中,SRS之前的栓塞导致AVMnal体积的统计学显着减少。因此,SRS治疗前栓塞可导致SRS治疗时的剂量减少,从而降低SRS并发症的风险,而栓塞并发症的发生率较高.
BACKGROUND: Arteriovenous malformations (AVMs) can be treated with observation, surgery, embolization, stereotactic radiosurgery (SRS), or a combination of therapies. SRS has been used for AVMs that pose a high risk of surgery, such as in deep or eloquent anatomic locations. Smaller AVMs, <3 cm, have been shown to have higher rates of complete obliteration after SRS. For AVMs that are a larger size, embolization prior to SRS has been used to reduce the size of the AVM nidus. In this study we analyzed embolization prior to SRS to reduce nidal volume and describe imaging techniques to target for SRS post embolization.
METHODS: We retrospectively reviewed all patients at a single academic institution treated with embolization prior to SRS for treatment of AVMs. We then used contrast enhanced magnetic resonance imaging (MRI) to contour AVM volumes based on pre-embolization imaging and compared to post-embolization imaging. Planned AVM volume prior to embolization was then compared to actual treated AVM volume.
RESULTS: We identified 11 patients treated with embolization prior to SRS from 2011-2023. Median AVM nidal volume prior to embolization was 7.69 mL and post embolization was 3.61 ML (P < 0.01). There was a 45.5% obliteration rate at follow up in our series, with 2 minor complications related to radiosurgery.
CONCLUSIONS: In our cohort, embolization prior to SRS resulted in a statistically significant reduction in AVM nidal volume. Therefore, embolization prior to SRS can result in dose reduction at time of SRS treatment allowing for decreased risk of SRS complications without higher embolization complication rates.